Asset Details
Do you wish to reserve the book?
Clinico‐sero‐pathological characteristics of anti‐Ha antisynthetase syndrome
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Clinico‐sero‐pathological characteristics of anti‐Ha antisynthetase syndrome
Do you wish to request the book?
Clinico‐sero‐pathological characteristics of anti‐Ha antisynthetase syndrome
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Clinico‐sero‐pathological characteristics of anti‐Ha antisynthetase syndrome
2025
Overview
To define the clinical, serological, and muscle histopathological characteristics, as well as treatment outcomes, of patients with anti‐Ha antibody. We performed a retrospective analysis of clinical, serological, and pathological data and long‐term treatment outcomes of anti‐Ha patients between January 2005 and July 2023 at our center. Anti‐Ha antibody was identified by immunoblot and reconfirmed by immunoprecipitation. Of the 570 patients with idiopathic inflammatory myopathies, 17 (3.0%) were found to be anti‐Ha positive, of whom 5 (29.4%) were also positive for another myositis‐specific antibody (MSA). All patients with anti‐Ha antibody as the single MSA (12/17, 70.6%) had clinical and histopathological evidence of muscle damage. Skin lesions were identified in nine of them (75%), while both interstitial lung disease and Raynaud's phenomenon were only seen in four patients. A necrotizing myopathy without a perifascicular pattern was the most common pathological manifestation (50%). Perifascicular necrosis (PFN) and myofiber major histocompatibility complex class‐II expression were observed only in one and four patients, respectively. Muscle weakness relapse was reported in five patients, and skin rashes worsening were observed in one patient. Most of the anti‐Ha patients (66.7%) finally achieved a favorable outcome at last follow‐up. Anti‐Ha antibody might not be as rare as previously thought and may coexist with other MSAs. Muscle damage is the most common manifestation in anti‐Ha patients, while extra‐muscular symptoms except for the cutaneous manifestations are unusual. The histopathological features varied with a predominance of necrotizing myopathy without PFN. These patients often finally had favorable outcomes, although relapses often occur. A necrotizing myopathy without a perifascicular pattern is the most common pathological manifestation of anti‐Ha ASS.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc
